Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836578 | 0.91 | ADORA3 (0.49) | SYKJAK2JAK3CDK4AURKA | |
| SCHEMBL4838626 | 0.87 | RAB9A (0.57) | RAB9ACTSSCTSKMEN1ALDH1A1 | |
| SCHEMBL14268811 | 0.86 | RAB9A (0.46) | RAB9ACTSSCTSKMEN1ALDH1A1 | |
| SCHEMBL4832652 | 0.86 | RAB9A (0.51) | PDGFRACCNE1CDK2RAB9ACTSS | |
| SCHEMBL4836468 | 0.86 | RAB9A (0.46) | RAB9ACTSSCTSKMEN1ALDH1A1 | |
| SCHEMBL4832892 | 0.86 | HTR2C (0.48) | RAB9ACTSSCTSKMEN1ALDH1A1 | |
| SCHEMBL14268895 | 0.86 | ACHE (0.47) | RAB9ACTSSCTSKALDH1A1SMN1; SMN2 | |
| SCHEMBL4829405 | 0.85 | ADORA3 (0.46) | SYKJAK3RAB9ABTKCTSS | |
| SCHEMBL4840315 | 0.84 | ACHE (0.49) | RAB9ACTSSCTSKMEN1ALDH1A1 | |
| SCHEMBL14274185 | 0.84 | RAB9A (0.44) | RAB9ACTSSCTSKMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173032-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-02-06 | — | — | US | claimed |
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-04-22 | — | — | US | claimed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-11-16 | — | — | US | disclosed |
| US-7132423-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-7112587-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-03 | — | — | US | disclosed |
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-10-13 | — | — | US | disclosed |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | NATIONAL BANK OF CANADA (CA) | 2005-06-23 | — | — | US | disclosed |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | disclosed |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | EGFR 157/4885SYK 764/4885JAK2 114/4885 |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | EGFR 94/4885SYK 527/4885JAK2 129/4885 |
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | MYLK, SMAD3, GID4 | EGFR 353/4885SYK 286/4885JAK2 42/4885 |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | EGFR 157/4885SYK 764/4885JAK2 114/4885 |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | EGFR 94/4885SYK 527/4885JAK2 129/4885 |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | EGFR 94/4885SYK 527/4885JAK2 129/4885 |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | EGFR 157/4885SYK 764/4885JAK2 114/4885 |
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | EGFR 157/4885SYK 764/4885JAK2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.